Latest news with #Pangea
Time Out
5 days ago
- Entertainment
- Time Out
Mendoza sounds: 11 must-listen bands from Mendoza
This band offers songs blending Soul, Jazz, Funk, Rock, and Hip-Hop elements, with touches of Latin sounds. They started making waves in the underground scene in 2010, evolving with natural musical maturation and sound experimentation. Their first album with the stable lineup—Nawel 'Chino' Lim, Tomás Lazzaro, Francisca Figueroa, Ricardo 'Tapa' Quirós, and Quito Pithod—came out in 2015. Their catalog includes the self-titled Spaghetti Western and Pangea, plus singles like 'Tiembla,' 'Ir y venir,' and 'Mansa buena onda,' which explore reflection, empowerment, and celebration of Latin roots. Their latest releases 'La Cobarde' and 'Yarará' mark a new musical era. Fun fact: They recently kicked off a national tour with fellow Mendoza band Pasado Verde, promising nights full of dancing and excitement. In Buenos Aires, they will play at Niceto Club on 05/28 and Auditorio Oeste on 05/30.
Yahoo
16-05-2025
- Business
- Yahoo
SYK Q1 Earnings Call: Stryker Delivers Revenue Beat, Cites International Growth and Tariff Headwinds
Medical technology company Stryker (NYSE:SYK) announced better-than-expected revenue in Q1 CY2025, with sales up 11.9% year on year to $5.87 billion. Its non-GAAP profit of $2.84 per share was 4% above analysts' consensus estimates. Is now the time to buy SYK? Find out in our full research report (it's free). Revenue: $5.87 billion vs analyst estimates of $5.68 billion (11.9% year-on-year growth, 3.2% beat) Adjusted EPS: $2.84 vs analyst estimates of $2.73 (4% beat) Adjusted EBITDA: $1.45 billion vs analyst estimates of $1.42 billion (24.7% margin, 2% beat) Adjusted EPS guidance for the full year is $13.33 at the midpoint, missing analyst estimates by 1% Operating Margin: 14.3%, down from 18.5% in the same quarter last year Free Cash Flow Margin: 2.2%, up from 0.7% in the same quarter last year Organic Revenue rose 10.1% year on year, in line with the same quarter last year Market Capitalization: $149.9 billion Stryker's first quarter results reflected healthy demand across both its MedSurg & Neurotechnology and Orthopaedics divisions, with management highlighting double-digit growth in its U.S. trauma, extremities, neurocranial, and surgical technologies segments. CEO Kevin Lobo emphasized the outperformance of new product platforms, especially the Mako robotic system and Pangea trauma plating system, as key contributors to market share gains. Management also pointed to continued strength in international markets, particularly Australia, New Zealand, Japan, and Europe, as a foundation for ongoing growth. Looking ahead, Stryker's 2025 guidance reflects the company's expectation for continued high-single-digit organic sales growth, while acknowledging several headwinds. CFO Preston Wells noted that tariffs—estimated to impact costs by $200 million this year—will require ongoing mitigation through pricing, supply chain optimization, and disciplined spending. Management cited strong order backlogs and robust demand for capital equipment as supportive factors, but recognized supply chain disruptions in the medical business and the need to integrate recent acquisitions like Inari Medical as considerations for the remainder of the year. Stryker's management attributed the quarter's performance to broad-based demand, new product uptake, and successful execution in core and emerging markets. The following insights summarize the major drivers behind the company's recent financial results: Robotic Surgery Momentum: The Mako robotic platform set a Q1 record for installations, with high utilization rates globally. Management expects continued growth in hips and knees as Mako expands into new indications and geographies. Product Innovation Pipeline: Recent launches, such as the LIFEPAK 35 defibrillator and the Pangea trauma plating system, drove meaningful sales growth. LIFEPAK 35 is set to expand into Europe and Japan, while Pangea will enter Australia and Canada this year and Japan in 2026. International Expansion: Stryker underscored strong growth in Australia, New Zealand, Japan, and Europe, citing these markets as significant future catalysts. The company expects regulatory delays to cause a lag between U.S. and international product uptake, but sees a multi-year runway for international sales. M&A and Portfolio Optimization: The acquisition of Inari Medical was completed, integrating into the vascular division. Stryker also finalized the sale of its U.S. Spinal Implants business, sharpening its strategic focus and capital allocation. Capital Equipment Demand: Management reported double-digit growth across capital businesses and stated that hospital capital spending remains robust, with a healthy order backlog and no current signs of a slowdown. Management expects Stryker's growth to be shaped by ongoing product launches, international expansion, and efforts to offset tariff-related cost pressures. The company's outlook is rooted in strong procedural demand, but it faces operational and macroeconomic uncertainties. Tariff Mitigation Efforts: Stryker plans to counteract the estimated $200 million tariff impact through pricing strategies, expense discipline, and supply chain optimizations. CFO Preston Wells noted that gross and operating margin improvement will depend on successfully executing these measures. Capital Equipment Backlog: The elevated order book for capital equipment is expected to support sales growth through the year, with management citing a six-month visibility into demand. Integration of Acquisitions and Divestitures: The performance of newly acquired Inari Medical and the transition of the U.S. Spinal Implants business out of the portfolio are expected to influence both revenue growth and margin profiles in coming quarters. Marcus Robert (JPMorgan): Pressed on how Stryker will absorb the $200 million tariff impact and what mitigation levers are most effective. Management cited sales momentum, pricing, and discretionary spending as key tools. Larry Biegelsen (Wells Fargo): Asked about the sustainability of operating margin expansion despite tariffs, with Preston Wells clarifying that margin gains will come from both gross margin and operating expense initiatives. Joanne Wuensch (Citi): Inquired about the ongoing integration of Inari Medical and whether there were any surprises post-acquisition. Management reported favorable early results and cultural alignment. Ryan Zimmerman (BTIG): Sought details on the international hip business's growth durability, with CEO Kevin Lobo attributing strong results to recent acquisitions and pending product launches in Europe and Asia-Pacific. Travis Steed (Bank of America): Questioned the details and geographic exposure of the tariff impact, as well as mitigation strategies for 2026. Management said future plans remain flexible due to the changing environment. In the coming quarters, the StockStory team will closely monitor (1) the rollout and adoption pace of new products such as Mako 4 and LIFEPAK 35 in both U.S. and international markets, (2) Stryker's ability to offset tariff-related cost pressures through pricing and operational efficiency, and (3) ongoing strength in capital equipment demand and procedural volumes globally. Additionally, we will watch for integration milestones with Inari Medical and any updates regarding regulatory changes or supply chain disruptions. Stryker currently trades at a forward P/E ratio of 28.4×. At this valuation, is it a buy or sell post earnings? Find out in our free research report. Market indices reached historic highs following Donald Trump's presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth. While this has caused many investors to adopt a "fearful" wait-and-see approach, we're leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years. Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today. Sign in to access your portfolio
Techday NZ
16-05-2025
- Business
- Techday NZ
Emerging AI security risks exposed in Pangea's global study
A global study by Pangea has highlighted emerging security weaknesses associated with the fast-paced deployment of AI systems in corporate environments. The research, which involved Pangea's USD $10,000 Prompt Injection Challenge, analysed almost 330,000 real-world attack attempts submitted by more than 800 participants from 85 countries. The challenge involved participants attempting to bypass AI security guardrails in three virtual rooms with increasing levels of difficulty in March 2025, generating extensive data on current AI security practices. The study was prompted by a sharp increase in the adoption of generative AI across numerous sectors, with enterprises using AI-powered applications for interactions involving customers, employees, and sensitive internal systems. The researchers observed that, despite this rapid uptake, specific AI-focused security measures have not kept pace in many organisations, which often rely primarily on default protections provided by AI models themselves. Pangea's dataset from the challenge revealed several vulnerabilities. A significant finding was the non-deterministic nature of large language model (LLM) security. Prompt injection attacks, a method where attackers manipulate input to provoke undesired responses from AI systems, were found to succeed unpredictably. An attack that fails 99 times could succeed on the 100th attempt with identical input, due to the underlying randomness in LLM processing. The study also revealed substantial risks of data leakage and adversarial reconnaissance. Attackers using prompt injection can manipulate AI models to disclose sensitive information or contextual details about the environment in which the system operates, such as server types and network access configurations. 'This challenge has given us unprecedented visibility into real-world tactics attackers are using against AI applications today,' said Oliver Friedrichs, Co-Founder and Chief Executive Officer of Pangea. 'The scale and sophistication of attacks we observed reveal the vast and rapidly evolving nature of AI security threats. Defending against these threats must be a core consideration for security teams, not a checkbox or afterthought.' Findings indicated that basic defences, such as native LLM guardrails, left organisations particularly exposed. The research showed that roughly 1 in 10 prompt injection attempts succeeded against these default protections, while multi-layered defences reduced the rate of successful attacks by significant margins. Agentic AI, where systems have greater autonomy and direct access to databases or tools, was found to amplify organisational risk. When compromised, such systems could potentially allow attackers to move laterally across networks, increasing the scope for harm. Joey Melo, a professional penetration tester and the only individual to successfully bypass all three virtual security rooms, spent two days developing a multi-layered strategy that ultimately defeated the single level of defence in room three. Joe Sullivan, former Chief Security Officer at Cloudflare, Uber and Facebook, commented on the risks highlighted by Pangea's research. 'Prompt injection is especially concerning when attackers can manipulate prompts to extract sensitive or proprietary information from an LLM, especially if the model has access to confidential data via RAG, plugins, or system instructions,' said Sullivan. 'Worse, in autonomous agents or tools connected to APIs, prompt injection can result in the LLM executing unauthorised actions—such as sending emails, modifying files, or initiating financial transactions.' In response to these findings, Pangea recommended a set of security measures for enterprises deploying AI applications. These include multi-layered guardrails to prevent prompt injection and data leakage, restriction of input languages and permitted operations in high-security environments, continuous red team testing specific to AI vulnerabilities, management of model randomness settings, and allocation of personnel or partners dedicated to tracking prompt injection threats. Friedrichs emphasised the urgency of the issue in his remarks. 'The industry is not paying enough attention to this risk and is underestimating its impact in many cases, playing a dangerous wait-and-see game. The rate of change and adoption in AI is astounding—moving faster than any technology transformation in the past few decades. With organisations rapidly deploying new AI capabilities and increasing their dependence on these systems for critical operations, the security gap is widening daily. The time to get ahead of these concerns is now.' Pangea's full research report, 'Defending Against Prompt Injection: Insights from 300K attacks in 30 days,' is publicly available.
